We focused on clear cell renal cell carcinoma (ccRCC), as a cancer where SETD2 mutations contribute to tumorigenesis (73), and lung adenocarcinoma, where SETD2 mutations are also known to occur (74). Here, SETD2 is linked to clear cell renal carcinoma.